Show simple item record

dc.contributor.authorDávila Fajardo, Cristina Lucía
dc.contributor.authorDíaz Villamarín, Xando 
dc.contributor.authorAntúnez Rodríguez, Alba
dc.contributor.authorFernández Gómez, Ana Estefanía
dc.contributor.authorGarcía Navas, Paloma
dc.contributor.authorMartínez González, Luis Javier 
dc.contributor.authorDávila Fajardo, José Augusto
dc.contributor.authorCabeza-Barrera, José
dc.date.accessioned2024-12-12T12:45:06Z
dc.date.available2024-12-12T12:45:06Z
dc.date.issued2019-04-01
dc.identifier.citationDávila Fajardo, C.L. et. al. Genes 2019, 10(4), 261. [https://doi.org/10.3390/genes10040261]es_ES
dc.identifier.urihttps://hdl.handle.net/10481/97957
dc.description.abstractThere is a special interest in the implementation of pharmacogenetics in clinical practice, although there are some barriers that are preventing this integration. A large part of these pharmacogenetic tests are focused on drugs used in oncology and psychiatry fields and for antiviral drugs. However, the scientific evidence is also high for other drugs used in other medical areas, for example, in cardiology. In this article, we discuss the evidence and guidelines currently available on pharmacogenetics for clopidogrel, warfarin, acenocoumarol, and simvastatin and its implementation in daily clinical practice.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectpharmacogeneticses_ES
dc.subjectclopidogreles_ES
dc.subjectwarfarines_ES
dc.titlePharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routinees_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/genes10040261
dc.type.hasVersionVoRes_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución 4.0 Internacional